ANI Pharmaceuticals, Inc. (ANIP) AI Stock Analysis

ANI Pharmaceuticals, Inc. specializes in the development, manufacturing, and distribution of branded and generic prescription pharmaceuticals across the United States and Canada. The company focuses on therapeutic areas such as controlled substances, oncology treatments, hormones, steroids, injectables, and various other formulations. Its manufacturing capabilities cover oral solid dose products, semi-solids, liquids, topicals, and potent formulations, along with contract development and manufacturing services. ANI Pharmaceuticals distributes its products through retail pharmacy chains, wholesalers, distributors, mail-order pharmacies, and group purchasing organizations to reach healthcare providers and patients.

Annual revenue increased from $216.1M in FY2021 to $316.4M in FY2022, $486.8M in FY2023, $614.4M in FY2024, and $883.4M in FY2025, reflecting a 5-year revenue CAGR of 33.5%. Net income shifted across these periods, recording -$42.6M in FY2021, -$47.9M in FY2022, $18.8M in FY2023, -$18.5M in FY2024, and $78.3M in FY2025. Gross margin contracted to 51.0% in FY2025 from 59.3% in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue grew 25.9% year-over-year while quarterly earnings rose 191.1% year-over-year, supporting trailing twelve month revenue of $978.4M and a profit margin of 11.1%.

As of June 30, 2026, ANI Pharmaceuticals held $375.9M in cash and short-term investments against total debt of $330.3M, leaving net cash of $45.5M. The current ratio stood at 2.91 with a debt-to-equity ratio of 0.55 against shareholders' equity of $597.2M. In FY2025, the business generated $185.2M in operating cash flow and $150.9M in free cash flow. Cash deployments in FY2025 included $34.3M in capital expenditures, $12.2M for share buybacks, and $1.2M in dividends paid.

At a last close of $72.29 on October 16, 2026, ANI Pharmaceuticals held a market capitalization of $1.66B and an enterprise value of $1.94B. The stock trades at a trailing P/E of 15.6x and a forward P/E of 7.1x, below the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its EV/EBITDA stands at 7.9x versus the peer median of 12.0x. Over the past year, the shares fell 21.4%, trailing the S&P 500 (SPY) gain of 16.8%, while its 5-year return of 87.6% exceeded the index return of 83.0%.

Wall Street analysts provide 4 Strong Buy, 3 Buy, and 2 Hold ratings, with 0 Sell or Strong Sell ratings. The mean price target of $105.78 sits 46.3% above the last close of $72.29. For the fiscal year ending December 31, 2026, consensus estimates target revenue of $1.10B and EPS of $9.26. ANI Pharmaceuticals beat EPS estimates in each of the trailing 4 quarters, and its next earnings date is November 6, 2026.

This page is an AI-written research summary of ANI Pharmaceuticals, Inc. (ANIP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ANIP income statement, ANIP balance sheet, ANIP key metrics, ANIP analyst forecast, ANIP chart. See the ANIP stock overview for the latest quote and news.